Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Mazurek, J.M. Malignant mesothelioma mortality—United States, 1999–2015. Morb. Mortal. Wkly. Rep. 2017, 66, 214–218. [Google Scholar] [CrossRef]
- Musk, A.; Olsen, N.; Alfonso, H.; Reid, A.; Mina, R.; Franklin, P.; Sleith, J.; Hammond, N.; Threlfall, T.; Shilkin, K. Predicting survival in malignant mesothelioma. Eur. Respir. J. 2011, 38, 1420–1424. [Google Scholar] [CrossRef] [PubMed]
- Wagner, J.C.; Sleggs, C.A.; Marchand, P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Occup. Environ. Med. 1960, 17, 260–271. [Google Scholar] [CrossRef]
- Howel, D.; Arblaster, L.; Swinburne, L.; Schweiger, M.; Renvoize, E.; Hatton, P. Routes of asbestos exposure and the development of mesothelioma in an English region. Occup. Environ. Med. 1997, 54, 403–409. [Google Scholar] [CrossRef] [PubMed]
- Van Gerwen, M.; Alpert, N.; Wolf, A.; Ohri, N.; Lewis, E.; Rosenzweig, K.E.; Flores, R.; Taioli, E. Prognostic factors of survival in patients with malignant pleural mesothelioma: An analysis of the National Cancer Database. Carcinogenesis 2019, 40, 529–536. [Google Scholar] [CrossRef] [PubMed]
- Vogelzang, N.J.; Rusthoven, J.J.; Symanowski, J.; Denham, C.; Kaukel, E.; Ruffie, P.; Gatzemeier, U.; Boyer, M.; Emri, S.; Manegold, C. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003, 21, 2636–2644. [Google Scholar]
- Zalcman, G.; Mazieres, J.; Margery, J.; Greillier, L.; Audigier-Valette, C.; Moro-Sibilot, D.; Molinier, O.; Corre, R.; Monnet, I.; Gounant, V. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial. Lancet 2016, 387, 1405–1414. [Google Scholar] [CrossRef]
- Baas, P.; Scherpereel, A.; Nowak, A.K.; Fujimoto, N.; Peters, S.; Tsao, A.S.; Mansfield, A.S.; Popat, S.; Jahan, T.; Antonia, S. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial. Lancet 2021, 397, 375–386. [Google Scholar] [CrossRef]
- Campbell, N.P.; Kindler, H.L. Update on malignant pleural mesothelioma. In Seminars in Respiratory and Critical Care Medicine; Thieme Medical Publishers: Chicago, IL, USA, 2011; pp. 102–110. [Google Scholar]
- Steele, J.P.; Shamash, J.; Evans, M.T.; Gower, N.H.; Tischkowitz, M.D.; Rudd, R.M. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2000, 18, 3912–3917. [Google Scholar] [CrossRef]
- Pinto, C.; Zucali, P.A.; Pagano, M.; Grosso, F.; Pasello, G.; Garassino, M.C.; Tiseo, M.; Parra, H.S.; Grossi, F.; Cappuzzo, F. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021, 22, 1438–1447. [Google Scholar] [CrossRef]
- Wolchok, J.D.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Rutkowski, P.; Lao, C.D.; Cowey, C.L.; Schadendorf, D.; Wagstaff, J.; Dummer, R. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J. Clin. Oncol. 2022, 40, 127–137. [Google Scholar] [PubMed]
- Long, G.V.; Luke, J.J.; Khattak, M.A.; de la Cruz Merino, L.; Del Vecchio, M.; Rutkowski, P.; Spagnolo, F.; Mackiewicz, J.; Chiarion-Sileni, V.; Kirkwood, J.M. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): Distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2022, 23, 1378–1388. [Google Scholar]
- Tykodi, S.S.; Gordan, L.N.; Alter, R.S.; Arrowsmith, E.; Harrison, M.R.; Singal, R.; Van Veldhuizen, P.; George, D.J.; Hutson, T.; Zhang, J. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: Results from the phase 3b/4 CheckMate 920 trial. J. Immunother. Cancer 2022, 10, e003844. [Google Scholar]
- Powles, T.; Plimack, E.R.; Soulières, D.; Waddell, T.; Stus, V.; Gafanov, R.; Nosov, D.; Pouliot, F.; Melichar, B.; Vynnychenko, I. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020, 21, 1563–1573. [Google Scholar]
- Reck, M.; Rodríguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csőszi, T.; Fülöp, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N. Engl. J. Med. 2016, 375, 1823–1833. [Google Scholar]
- Herbst, R.S.; Giaccone, G.; de Marinis, F.; Reinmuth, N.; Vergnenegre, A.; Barrios, C.H.; Morise, M.; Felip, E.; Andric, Z.; Geater, S. Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC. N. Engl. J. Med. 2020, 383, 1328–1339. [Google Scholar] [PubMed]
- Sezer, A.; Kilickap, S.; Gümüş, M.; Bondarenko, I.; Özgüroğlu, M.; Gogishvili, M.; Turk, H.M.; Cicin, I.; Bentsion, D.; Gladkov, O. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: A multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet 2021, 397, 592–604. [Google Scholar] [CrossRef]
- Maio, M.; Scherpereel, A.; Calabrò, L.; Aerts, J.; Perez, S.C.; Bearz, A.; Nackaerts, K.; Fennell, D.A.; Kowalski, D.; Tsao, A.S. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017, 18, 1261–1273. [Google Scholar] [PubMed]
- Popat, S.; Curioni-Fontecedro, A.; Dafni, U.; Shah, R.; O’Brien, M.; Pope, A.; Fisher, P.; Spicer, J.; Roy, A.; Gilligan, D. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: The European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann. Oncol. 2020, 31, 1734–1745. [Google Scholar]
- Fennell, D.A.; Ewings, S.; Ottensmeier, C.; Califano, R.; Hanna, G.G.; Hill, K.; Danson, S.; Steele, N.; Nye, M.; Johnson, L. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): A multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021, 22, 1530–1540. [Google Scholar]
- Gogishvili, M.; Melkadze, T.; Makharadze, T.; Giorgadze, D.; Dvorkin, M.; Penkov, K.; Laktionov, K.; Nemsadze, G.; Nechaeva, M.; Rozhkova, I. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: A randomized, controlled, double-blind phase 3 trial. Nat. Med. 2022, 28, 2374–2380. [Google Scholar] [PubMed]
- Mok, T.S.; Wu, Y.L.; Kudaba, I.; Kowalski, D.M.; Cho, B.C.; Turna, H.Z.; Castro, G.; Srimuninnimit, V.; Laktionov, K.K.; Bondarenko, I. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet 2019, 393, 1819–1830. [Google Scholar] [PubMed]
- Isik, R.; Metintas, M.; Gibbs, A.; Metintas, S.; Jasani, B.; Öner, Ü.; Harmanci, E.; Demircan, S.; Işiksoy, S. p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: Correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure. Respir. Med. 2001, 95, 588–593. [Google Scholar]
- Şenyiğit, A.; Babayiğit, C.; Gökirmak, M.; Topçu, F.; Asan, E.; Coşkunsel, M.; Işık, R.; Ertem, M. Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the southeast of Turkey. Respiration 2000, 67, 610–614. [Google Scholar] [PubMed]
- Selçuk, Z.T.; Çöplü, L.; Emri, S.; Kalyoncu, A.F.; Şahin, A.A.; Bariş, Y.I. Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey: Analysis of 135 cases. Chest 1992, 102, 790–796. [Google Scholar]
- Metintas, M.; Özdemir, N.; Hillerdal, G.; Uçgun, I.; Metintas, S.; Baykul, C.; Elbek, O.; Mutlu, S.; Kolsuz, M. Environmental asbestos exposure and malignant pleural mesothelioma. Respir. Med. 1999, 93, 349–355. [Google Scholar]
- Menis, J.; Pasello, G.; Remon, J. Immunotherapy in malignant pleural mesothelioma: A review of literature data. Transl. Lung Cancer Res. 2021, 10, 2988–3000. [Google Scholar]
n = 60 (%) | |
---|---|
Age, years, median | 59 (34–83) |
Gender | |
Male | 35 (58.3) |
Female | 25 (41.7) |
ECOG PS | |
0 | 18 (30) |
1–2 | 42 (70) |
Smoking | |
Yes | 22 (36.7) |
No | 37 (61.7) |
Unknown | 1 (1.6) |
Histopathological type | |
Epithelioid | 43 (71.7) |
Sarcomatoid or biphasic | 12 (20) |
Others | 5 (8.3) |
Distant metastasis | |
Yes | 17 (28.3) |
No | 43 (71.7) |
Perioperative Therapy | |
Yes | 24 (40) |
No | 36 (60) |
Previous radiation therapy | |
Yes | 29 (48.3) |
No | 31 (51.7) |
Type of surgery (n = 24) | |
EPP | 7 (29.2) |
PD | 16 (66.7) |
Others | 1 (4.1) |
Steroid use | |
No | 48 (80) |
Yes | 12 (20) |
Asbestos exposure | |
Living in an endemic region | 39 (65) |
Other | 21 (35) |
PD-L1 status | |
Unknown | 43 (71.7) |
≥1% | 13 (21.7) |
<1% | 4 (6.7) |
n (%) | |
---|---|
First-line treatment options (n = 60) | |
Nivolumab + ipilimumab | 3 (5) |
Nivolumab | 6 (10) |
Platinum-based Ch + beva | 15 (25) |
Platinum-based Ch | 27 (45) |
Other Ch | 7 (11.7) |
Pembrolizumab | 2 (3.3) |
Second-line treatment options (n = 57) | |
Nivolumab + ipilimumab | 3 (5.3) |
Nivolumab | 24 (42.1) |
Platinum-based Ch + beva | 4 (7) |
Platinum-based Ch | 18 (31.6) |
Other Ch | 8 (14) |
Subsequent treatment options (n = 32) | |
Nivolumab + ipilimumab | 1(3.1) |
Nivolumab | 21 (65.6) |
Chemotherapy | 10 (31.3) |
Immunotherapy, any line (n = 60) | |
Nivolumab + ipilimumab | 7 (11.7) |
Nivolumab | 51 (85) |
Pembrolizumab | 2 (3.3) |
n (%) | ORR % | p | mPFS (mo) | p | mOS (mo) | p | |
---|---|---|---|---|---|---|---|
First-line treatment options (n = 60) | 0.97 * | 0.50 ** | 0.49 ** | ||||
Immunotherapy | 11 (18.3) | 6 (54.5) | 9 | 15 | |||
Chemotherapy | 49 (81.7) | 27 (55.1) | 6 | 21 | |||
Second-line treatment options (n = 57) | 0.78 * | 0.30 ** | |||||
Immunotherapy | 27 (47.4) | 9 (33.3) | 3 | ||||
Chemotherapy | 30 (52.6) | 9 (30) | 6 | ||||
Subsequent treatment options (n = 32) | 0.35 * | 0.048 ** | |||||
Immunotherapy | 22 (68.8) | 10 (47.6) | 6 | ||||
Chemotherapy | 10 (31.2) | 3 (30) | 3 | ||||
Immunotherapy, any line (n = 60) | 0.42 *** | 0.44 ** | 0.64 ** | ||||
Nivolumab + ipilimumab | 7 (11.7) | 4 (57.1) | 4 | 31 | |||
Nivolumab or pembrolizumab | 53 (88.3) | 20 (37.7) | 4 | 18 |
Univariate Analysis | Multivariate Analysis | |||||
---|---|---|---|---|---|---|
HR | 95% CI | p | HR | 95% CI | p | |
Age, years (<58 */≥58) | 0.60 | 0.34–1.07 | 0.08 | |||
Gender (female */male) | 0.89 | 0.50–1.58 | 0.70 | |||
ECOG PS (0 */1–2) | 1.36 | 0.75–2.47 | 0.36 | |||
Smoking (no */yes) | 0.94 | 0.52–1.72 | 0.85 | |||
Histological subtypes (epithelioid */others) | 0.88 | 0.46–1.67 | 0.71 | |||
Asbestos exposure (endemic region */others) | 1.10 | 0.60–2.01 | 0.74 | 4.16 | 1.04–16.7 | 0.04 |
Previous radiation therapy (no */yes) | 1.10 | 0.62–1.94 | 0.74 | |||
PD-L1 (<1% */≥1%) | 0.98 | 0.25–3.83 | 0.98 | |||
Distant metastasis (no */yes) | 1.37 | 0.73–2.57 | 0.32 | 4.59 | 1.02–20.7 | 0.04 |
Treatment line (first */subsequent) | 1.38 | 0.67–2.88 | 0.37 | |||
Treatment option (mono IO */combination IO) | 0.72 | 0.28–1.82 | 0.48 | |||
Steroid use (no */yes) | 0.95 | 0.47–1.93 | 0.89 |
n | ORR % | p | mPFS (mo) | p (log-Rank) | |
---|---|---|---|---|---|
Age (years) | 0.20 * | 0.06 | |||
<58 | 26 | 8 (30.8) | 3 | ||
≥58 | 34 | 16 (47.1) | 5 | ||
Gender | 0.59 * | 0.67 | |||
Female | 25 | 9 (36) | 4 | ||
Male | 35 | 15 (42.9) | 4 | ||
Smoking | 0.66 * | 0.84 | |||
No | 37 | 16 (42.1) | 4 | ||
Yes | 22 | 8 (36.4) | 4 | ||
Histological subtypes | 0.55 * | 0.68 | |||
Epithelioid | 43 | 18 (41.9) | 4 | ||
Others | 17 | 6 (35.3) | 3 | ||
Asbestos exposure | 0.43 * | 0.62 | |||
Endemic region | 39 | 17 (43.6) | 4 | ||
Others | 21 | 7 (33.3) | 4 | ||
Previous radiation therapy | 0.68 * | 0.73 | |||
No | 31 | 12 (38.7) | 3 | ||
Yes | 29 | 12 (41.4) | 4 | ||
PD-L1 | 0.58 ** | 0.98 | |||
<1% | 4 | 2 (50.0) | 4 | ||
≥1% | 13 | 9 (69.2) | 6 | ||
Distant metastasis | 0.48 * | 0.26 | |||
No | 43 | 16 (37.2) | 4 | ||
Yes | 17 | 8 (47.1) | 3 | ||
Treatment line | 0.32 ** | 0.32 | |||
First line | 11 | 6 (54.5) | 6 | ||
Subsequent | 49 | 18 (36.7) | 3 | ||
Treatment option | 0.42 ** | 0.44 | |||
Mono IO | 53 | 20 (37.7) | 4 | ||
Combination IO | 7 | 4 (57.1) | 4 | ||
Steroid use | 0.74 * | 0.88 | |||
No | 48 | 20 (41.7) | 4 | ||
Yes | 12 | 4 (33.3) | 4 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Published by MDPI on behalf of the Lithuanian University of Health Sciences. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kalkan, Z.; Ebinc, S.; Arcagok, M.; Bilici, A.; Yildiz, O.; Kilickap, S.; Guven, D.C.; Tatli, A.M.; Sumbul, A.T.; Mandel, N.M.; et al. Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study. Medicina 2025, 61, 638. https://doi.org/10.3390/medicina61040638
Kalkan Z, Ebinc S, Arcagok M, Bilici A, Yildiz O, Kilickap S, Guven DC, Tatli AM, Sumbul AT, Mandel NM, et al. Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study. Medicina. 2025; 61(4):638. https://doi.org/10.3390/medicina61040638
Chicago/Turabian StyleKalkan, Ziya, Senar Ebinc, Murat Arcagok, Ahmet Bilici, Ozcan Yildiz, Saadettin Kilickap, Deniz Can Guven, Ali Murat Tatli, Ahmet Taner Sumbul, Nil Molinas Mandel, and et al. 2025. "Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study" Medicina 61, no. 4: 638. https://doi.org/10.3390/medicina61040638
APA StyleKalkan, Z., Ebinc, S., Arcagok, M., Bilici, A., Yildiz, O., Kilickap, S., Guven, D. C., Tatli, A. M., Sumbul, A. T., Mandel, N. M., Ozturk, A., Bardakci, M., Karakaya, S., & Kaplan, M. A. (2025). Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study. Medicina, 61(4), 638. https://doi.org/10.3390/medicina61040638